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Abstract
Background: Lung cancer remains the leading cause of cancer death worldwide. Radioresistance of lung cancer cells results
in unacceptable rate of loco-regional failure. Although radiation is known to induce apoptosis, our recent study showed that
knockdown of pro-apoptotic proteins Bak and Bax resulted in an increase in autophagic cell death and lung cancer
radiosensitivity in vitro. To further explore the potential of apoptosis inhibition as a way to sensitize lung cancer for therapy,
we tested M867, a novel chemical and reversible caspase-3 inhibitor, in combination with ionizing radiation in vivo and in
vitro.
Methods and Findings: M867 reduced clonogenic survival in H460 lung cancer cells (DER=1.27, p=0.007) compared to the
vehicle-treated treated cells. We found that administration of M867 with ionizing radiation in an in vivo mouse hind limb
lung cancer model was well tolerated, and produced a significant tumor growth delay compared to radiation alone. A
dramatic decrease in tumor vasculature was observed with M867 and radiation using von Willebrand factor staining. In
addition, Ki67 index showed .5-fold reduction of tumor proliferation in the combination therapy group, despite the
reduced levels of apoptosis observed with terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining.
Radiosensitizing effect of M867 through inhibiting caspases was validated using caspase-3/-7 double-knockout (DKO)
mouse embryonic fibroblasts (MEF) cell model. Consistent with our previous study, autophagy contributed to the
mechanism of increased cell death, following inhibition of apoptosis. In addition, matrigel assay showed a decrease in in
vitro endothelial tubule formation during the M867/radiation combination treatment.
Conclusions: M867 enhances the cytotoxic effects of radiation on lung cancer and its vasculature both in vitro and in vivo.
M867 has the potential to prolong tumor growth delay by inhibiting tumor proliferation. Clinical trials are needed to
determine the potential of this combination therapy in patients with locally advanced lung cancer.
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Introduction
Lung cancer is the most prevalent cancer worldwide, and the
leading cause of cancer-related mortality despite multi-modality
therapy, resulting in 160,390 estimated deaths in the United States
only in 2007 [1]. Since tumor resistance limits effectiveness of
current treatments [2,3,4], such as radiotherapy, the identification
of novel therapeutic strategies is critical for improving outcome. Of
the different cell death processes involved in cancer treatment,
apoptosis has been the most well-studied [5]. During apoptosis,
the major mediators of cellular destruction are effectors caspase-3
and -7, members of the cysteine aspartate proteases family,
which cleave proteins after an aspartate residue [6]. Although
radiation is known to induce apoptosis, yet it accounts for a
minor portion of cell death in irradiated solid tumors [7], and
our recent study showed that knockdown of pro-apoptotic
proteins Bak and Bax resulted in an increase in lung cancer
radiosensitivity in vitro [8]. Autophagy, a non-apoptotic cell death
type, was shown to contribute to the mechanism of increased cell
death.
Autophagy is an evolutionarily conserved process and a survival
mechanism allowing for the recycling of long-lived organelles and
proteins [9,10]. Autophagy also serves as a suicide pathway with
complete self-digestion under excessive stress conditions [11,12],
which is classified as programmed cell death Type 2 [9,10].
During autophagy, organelle degradation occurs through forma-
tion of cytoplasmic double-membrane vacuoles, called autophago-
somes with intact nuclei [13]. Autophagy regulation has been of
increasing interest, because of its implication in tumorigenesis. In
addition, prolonged autophagy can lead to cancer cell death,
leading to the hypothesis that autophagy can be exploited as a
cancer therapy target [14,15,16,17].
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2275To further explore the potential of apoptosis inhibition as a way
to sensitize lung cancer for therapy, we tested M867, a novel
chemical and reversible caspase-3 inhibitor [18], in combination
with ionizing radiation in vivo and in vitro.
Materials and Methods
Cell culture
Primary mouse embryonic fibroblasts (MEFs) were derived from
wild-type (WT) and Caspase3
2/2/7
2/2 double knockout (DKO)
mice and immortalized by transfection with a plasmid containing
SV40-T-antigen (provided by Dr. Richard Flavell, Yale Univer-
sity, New Haven, CT). MEFs were cultured in DMEM (Invitrogen
Corporation) supplemented with 10% fetal bovine (FBS), 1%
penicillin-streptomycin and 0.5 mmol/L 2-mercaptoethanol. H460
lung cancer cells were cultured in RPMI 1640 (Invitrogen, Grand
island, NY) supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin at 37uC and humidified 5% CO2.
HUVECs were obtained from Clonetics and were maintained in
EBM-2 medium supplemented with EGM-2 MV single aliquots
(BioWhittaker). M867 was obtained from Merck & Co., Inc.
Clonogenic Assay
H460 lung cancer cells were treated with DMSO or M867
(1.4nM, 5nM, and 10nM for 24hrs); WT MEFs cells and caspase
3/7 DKO MEFs cells were treated with DMSO or M867 (5nM
and 10nM for 24hrs); and MEFs cells were treated with siRNAs
against caspase-3 and-7, siRNAs against Beclin-1 and ATG5, or
control. Cells were then irradiated with 0 to 6 Gy as indicated at a
dose rate of 1.8 Gy/min, by using of a
137 Cs irradiator (J.L.
Shepherd and Asssociates, Glendale, CA). After irradiation, cells
were incubated at 37uC for 8–10 days. Cells were fixed for 15min
with 3:1 methanol: acetic acid and stained for 15min with 0.5%
crystal violet (Sigma) in methanol. After staining, colonies were
counted using a cutoff of 50 viable cells. Surviving fraction was
calculated as (mean colony counts)/(cells inoculated)6(plating
efficiency (PE)), where PE was defined as (mean colony counts)/
(cells inoculated for non-irradiated controls). DER was calculated
as the dose (Gy) for radiation alone divided by the dose (Gy) for
radiation plus M867 (normalized for M867 toxicity) necessary for
a surviving fraction of 0.25. Experiments were conducted in
triplicate and mean, SD, and P values were calculated.
Immunoblotting
Cells (0.5610
6) were treated with various Gy and drugs. They
were collected at various time points, and then were washed with
ice-cold PBS twice before the addition of lysis buffer (20mM Tris-
HCl, pH 7.4, 150mM NaCl, 20mM EDTA, 1% NP40, 50mM
NaF, 1mM Na3Vo4, 1mM NaMO4 and cocktail inhibitor (Sigma,
5ul/ml). Protein concentration was quantified by the Bio-Rad
method. Equal amounts of protein were loaded into each well and
separated by 12.5% SDS-PAGE gel, followed by transfer onto
PVDF-membranes (BIO-RAD). Membranes were blocked by use
5% nonfat dry milk in PBS-T for 1h at room temperature. The
blots were then incubated with Caspase-3 (Cell signaling);
Caspase-7 (Cell signaling); LC-3 (Medical& Biological Laborato-
ries Co. LTD); Akt, phospho-Akt (Ser-473), S6 ribosomal protein,
and phospho-S6 ribosomal protein (Ser-240/244) (Cell Signaling);
and Actin antibodies for 1hr at 4uC. Goat anti-rabbit IgG
secondary (1:5000, Santa Cruse Biotechnologies) was incubated
for 45min at room temperature. Immunoblots were developed by
using the chemiluminescence detection system (PerkinElmer)
according to the manufacture’s protocol and autoradiography.
Measurement of Apoptosis
Cells (2.5610
5) were plated into 10mm dishes for each data
point. After 24 h of 37uC incubation, H460 cells were treated with
M867 (100nM for 2 hours) and immediately irradiated with 5Gy,
10Gy or 20Gy, and WT and Caspase3
2/2/7
2/2 DKO cells were
irradiated with 5Gy or 10Gy. After 24h, cells were treated with
1ml of Accutase (keeping all floating cells) for 4min and then
counted for each sample. Cells were centrifuged and re-suspended
in 16Binding Buffer at a concentration of ,1610
6 cells/ml.
100 ml of the solution (,1610
5 cells) were transferred in 5ml
FACS tube, added with 1.2 ml of Annexin V FITC and 1.2 mlo f
PI. After incubation for 30 min at RT in the dark, 400 mlo f1 6
Binding Buffer were added to each tube. The rate of apoptosis was
measured using the Annexin V-fluorescein isothiocyanate apopto-
sis detection kit I (Pharmingen) with flow cytometry.
Autophagy Assay
MEFs Cells were transfected with 2.5 mg of GFP-LC3
expression plasmid (gift from Dr. Norboru Mizushima) [19] using
the lipofectamine reagent (Invitrogen Life Technologies). After
24h, cells were treated with 5Gy of radiation, with or without dose
M867. After 24h and 48h, the fluorescence of GFP-LC3 was
observed using confocal fluoroscopy.
siRNA Transfection
siRNAs against mouse caspase-3 and-7, Beclin, and control
siRNA were purchased from Santa Cruz Biotechnologies. siRNA
ATG5(mouse) was synthesized by Dharmacon Research. The
sense and antisense strands of ATG5 were begun at nucleotide, 59-
AACUUGCUUUACUCUCUCAUCAUU-39 (Sense) and 39-
UUUUGAACGAAAUGAGAGAUAGU-59. (Antisense) Cells
were transfected with 25nM of siRNAs using LipofectAMINE
2000. The transfected cells were used for experiments 24h later.
Endothelial Cell Morphorgenesis assay: Tubule Formation
HUVECs grown to ,70% confluency were treated with 5nM
M867, 3Gy, or combination therapy. Cells were then trypsinized
and counted. They were seeded at 48000 per well on 24-well
plates coated with 300 ml of Matrigel (BD Biosciences). These cells
undergo differentiation into capillary-like tube structures period-
ically observed by microscopy. 24h later, cells were stained with
hematoxylin and eosin (H&E) and photographs were taken via
microscope. The average number of tubules was calculated from
examination of three separate microscopic fields (1006) and
representative photographs were taken.
Tumor volume assessment
Human H460 lung cancer cells were used in a xenograft model
in female athymic nude mice (nu/nu), 5–6 weeks old [Harlan
Sprague Dawley Inc., Indianapolis, IN]). A suspension of 1610
6
cells in 50 mL volume was injected subcutaneously into the left
posterior flank of mice using a 27K-gauge needle. Tumors were
grown for 6–8d until average tumor volume reached 0.25cm
3.
Treatment groups consisted of vehicle control (in DMSO), M867,
vehicle plus radiation, and M867 plus radiation. Each treatment
group contained 5 mice. DMSO or M867 was given daily by
intraperitoneal (i.p.) injection at doses of 2mg/kg for 7 consecutive
days. In the case of combination treatment, drug or vehicle was
given for 2d prior to the first dose of irradiation. Mice in radiation
groups were irradiated 1h after drug or vehicle treatment with
daily 2Gy fractions given over 5 consecutive days. Tumors on the
flanks of the mice were irradiated using an X-ray irradiator
(Therapax, Agfa NDT, Inc., Lewis Town, PA). The non-tumor
Caspase Inhibition
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were measured 2–3 times weekly in 3 perpendicular dimensions
using a Vernier caliper and volume was calculated using the
modified ellipse volume formula (volume=(height6width6
depth)/2). Growth delay was calculated for treatment groups
relative to control tumors.
Histological sections, vWF, ki67 and TUNEL staining
Mice were implanted with H460 cells and treated as described
above in the tumor volume studies. After 7d of daily treatments,
mice were sacrificed and tumors were paraffin fixed. Slides from
each treatment group were then stained for von Willebrand factor
(vWF) using anti-vWF polyclonal antibody (Chemicon). Blood
vessels were quantified by randomly selecting 4006 fields and
counting the number of blood vessels per field. This was done in
triplicate and the average of the three counts was calculated. Ki67
and terminal deoxynucleotidyl transferase-mediated dUTP nick
end labeling (TUNEL) staining were performed in the Vanderbilt
University pathology core laboratory using standard protocols.
Number of positive cells per field were scored and graphed by
averaging three repeated assessments.
Statistical analysis
Analysis of study results focused on testing the differences of the
mean tumor volume among treatment groups and different time
points. The data analysis was completed using the restricted/
residual maximum likelihood-based mixed-effect model to adjust
the intracorrelation effect for the mice that had multiple
measurements. The model reported in the paper was selected on
the basis of the Schwarz’s Bayesian criterion. All tests of
significance were 2-sided, and differences were considered
statistically significant when p was less than 0.05. A statistical
package, SAS v8.2, was used for all analyses.
Results
M867 inhibited apoptosis but enhanced radiation
sensitivity in H460 lung cancer cells
To test the effect of inhibition of caspase-3 on lung cancer
sensitivity to radiation, H460 cells were treated with novel
reversible inhibitor M867 in combination with ionizing radiation.
Surviving colonies were counted 8 days later. Clonogenic survival
assay, shown in Figure 1A, demonstrated a decreased survival in
various dose groups, with 10nM of M867 resulting in the greatest
enhancement in radiosensitivity, as compared to control
(DER=1.27, p=0.007). The level of apoptosis in H460 cells
was measured after M867 treatment (100nM for 2h) and
irradiation with 5Gy to 20Gy, using Annexin-V assay. It has
been previously shown that Annexin V binding was blocked by
M867 with an IC50 of 80 nM [20]. As shown in Figure 1B, the
level of apoptosis was progressively elevated with increased doses
of radiation. 20% of irradiated H460 cells were apoptotic at 20
Gy. When M867 was given prior to radiation, apoptotic cells were
decreased to half at both low and high dose levels of radiation.
These results demonstrate that sensitization of H460 lung cancer
cells to ionizing radiation was associated with decreased apoptosis.
Combined M867/radiation treatment prolongs tumor
growth delay and is well-tolerated in lung xenograft
model.
Having established the effectiveness in vitro for M867-induced
radiosensitization of lung cancer cells, a mouse hind limb
xenograft model was generated to explore the radiation response
by M867 in vivo. H460 lung cancer cells were injected
subcutaneously into athymic nude mice, and tumors were allowed
to grow for approximately 7 days to produce an average tumor
volume of 0.25cm
3 prior to therapy. The treatment groups
consisted of a vehicle control, M867, vehicle plus radiation, and
combination of M867 plus radiation. M867 was administered
daily by 2mg/kg intraperitoneal injection for 7 consecutive days.
Hind limb H460 tumor xenografts in mice were treated as
described in the Material and Methods section. Growth delay was
calculated as the number of days required to reach a tumor
volume of 2 cm
3 for treatment groups relative to control tumors.
As shown in Figure 2A, a significant tumor growth delay was seen
with combination therapy of M867 and radiation compared to
irradiation alone (26 vs 20 days, p,0.005), and M867 alone did
also significantly affect the tumor growth compared to control
(,4 days delay, p=0.003). This suggests that M867 could increase
tumor response in combination with radiotherapy. In addition, the
body weight changes were also tracked in the mice to assess
whether treatment with M867, radiation, or combination
treatment yielded systemic toxicity (Figure 2B). Only minimal
weight loss was seen at 10 days following the combined M867 and
irradiation treatment. Changes in body weight after this time
period reflected tumor growth. As expected, the combination
treatment group, which had the most prolonged tumor growth
delay, had the smallest increase in body weight.
M867 reduces tumor proliferation index despite marked
decrease in apoptosis in irradiated H460 mouse
xenograft
To determine the mechanism that contributes to the tumor
growth delay following the combination therapy, Ki67 prolifera-
tive index was examined using fixed H460 tumor sections in all
treatment groups. As shown in Figure 3A, M867 plus radiation
combination treatment resulted in a 6-fold (15% vs 92%,
p,0.001) and 2-fold (15% vs 33%, p,0.001) reduction in
proliferating cells compared to control and radiation alone groups,
respectively. We next assessed apoptosis levels in fixed H460
tumor sections using TUNEL staining. As shown in Figure 3B
using TUNEL staining, combined M867 and radiation treatment
resulted in two-thirds reduction in apoptosis (4.5% vs 15%,
p,0.008), compared to radiation alone.
M867 reduces vascular density in irradiated lung tumor
model and sensitizes HUVECs to radiation
Since tumor vasculature is a target for cancer treatment, mice
were treated similarly to those in the tumor growth delay study
and fixed lung tumor sections were used to determine the effects of
M867 and radiation on tumor vasculature in vivo. Slides from each
treatment group were analyzed following von Willebrand Factor
(vWF) staining for vascular density study, as shown in Figure 4A.
The number of vessels per microscopic field was then determined
for each treatment group. Combination therapy of M867 and
radiation (1.3; SD=0.57) resulted in a dramatic 5-fold reduction
in the average number of vessels per microscopic field in
comparison to control (6; SD=1; p,0.002) and a ,2-fold
reduction relative to radiation therapy alone (2.3; SD=0.57;
p,0.007) (Figure 4A).
To further investigate the effects of M867 and radiation on
blood vessel formation, human umbilical vein endothelial cells
(HUVECs) were used to examine tubules formation for angiogenic
function in vitro. The endothelial cell morphogenesis assay was
done to examine the ability of treated HUVECs to produce
capillary-like tubular structures. A representative image and the
Caspase Inhibition
PLoS ONE | www.plosone.org 3 May 2008 | Volume 3 | Issue 5 | e2275Figure 1. M867 inhibits apoptosis and reduces clonogenic survival of H460 lung cancer cells. (A) H460 NSCLC cells were treated with
DMSO control, M867 (dose range from 1.4 to 10 nM, for 24hrs) with radiation. After 8 d, colonies were stained and the scored colonies were graphed.
Survival curves for H460 cells6M867 treatment. Points, mean; bars, SD (P=0.007). Shown are the mean +/2 the standard deviation of three separate
repeated experiments. (B) Annexin-V assay showing the level of apoptosis in H460 cells treated by either control, 100nM of M867 for 2h, radiation (5,
10 or 20 Gy), and both modality. This was done in triplicate and the average of the three counts was calculated. Columns, average; bars, SD.
doi:10.1371/journal.pone.0002275.g001
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PLoS ONE | www.plosone.org 4 May 2008 | Volume 3 | Issue 5 | e2275Figure 2. Extended tumor growth delay with M867 and radiotherapy at well-tolerated doses in xenografted H460 model. H460 lung
cancer cells were xenografted subcutaneously in athymic mice. After 6–8 days, mice were treated daily for 7 days, with vehicle control, M867 (2mg/
kg), and then were treated 1 hour after drug treatment with 2 Gy of radiation, daily over 5 consecutive days. Tumor was excised when reached the
size of approximately 2.5–3.0 cm
3 and tumor growth delay as defined by the number of days required to reach a tumor volume of 2 cm
3 was
measured. (A) Tumors were measured regularly and growth delay was calculated for treatment groups relative to control tumors. The combined bi-
modality therapy induced a marked tumor growth delay when compared with radiation alone (26 vs 20 days, p,0.005). (B) Body weights were
measured every 5 days and body weight ratio was calculated relative to baseline measurement.
doi:10.1371/journal.pone.0002275.g002
Caspase Inhibition
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shown in Figure 4B and C, respectively. Treatment with M867
combined to radiation significantly decreased tubule formation
compared to radiation alone (5.7 vs 1.7, p,0.001). No treatment
control had 13 tubules (SD=1.0) per microscopic field and M867
alone had 9 tubules (SD=1.0), suggesting an anti-angiogenic effect
of M867 in addition to the radio-sensitization.
Caspase 3/7 deficiency promotes radiation sensitivity by
autophagy induction, in the absence of apoptosis
To validate whether inhibition of caspases contributed to
enhancing radiation therapy, caspase-3/7 deficient (DKO) MEF
cells were used. These cells are unable to undergo apoptosis, since
they lack caspases 3/7, whereas WT MEFs can (Figure 5A and
5B). As shown in Figure 5C, WT MEFs treated with M867 were
Figure 3. M867 with radiation reduces Ki67 proliferative marker and increases apoptotic index in H460 xenograft tumor models.
Histologic sections were obtained from the tumors of the mice in each treatment group from the tumor volume study. Number of positive cells were
scored and graphed by averaging three repeated assessments. (A) Average Ki67 proliferative index of each treatment group was determined by the
percent of Ki67-positive cells per microscopic field. This was repeated thrice. Columns, mean; bars, SD. (B) TUNEL staining was also performed on
tumor sections, and apoptotic index was similarly calculated by percent of positive TUNEL stained cells per microscopic field. Column, mean; bars, SD.
doi:10.1371/journal.pone.0002275.g003
Figure 4. M867 sensitizes vascular endothelial in vitro model to ionizing radiation and reduces in vivo vascular density in irradiated
H460 tumors. (A) Histologic sections were obtained from the tumors of the mice in each treatment group from the in vivo tumor volume study, and
stained for blood vessels using an antibody for vWF. Blood vessels were quantified by randomly selecting 4006fields and counting the number of
blood vessels per field. This was done in triplicate and the average of the three counts was calculated. Columns, average; bars, SD. (B) Human
umbilical vein endothelial cells (HUVECs) were treated with 5 nM M867 and then immediately irradiated with either 0 or 3 Gy. Six hours later, cells
were trypsinized and replated on 24-well plates coated with Matrigel. After 24 h, cells were fixed and stained with H&E. The slides were examined by
microscopy (6100), and representative fields are shown. (C) Stained tubules were then counted in three separate, randomly selected fields. Columns,
mean number of tubules counted per microscopic field; bars, SD.
doi:10.1371/journal.pone.0002275.g004
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with DMSO (DER=1.2 for 5nM M867, p=0.017, and
DER=1.62 for 10NM M867, p=0.001). There was no significant
difference in survival among the caspase DKO MEFs treated with
any dose of M867 as compared to DMSO. In addition, WT MEFs
cells transfected with caspase-3/7 siRNAs also presented signifi-
cant increase in the radiation sensitivity, suggesting that these
results are not due to clonal variation of these cells (data not
shown). Based on our previous study, we hypothesize that
enhanced radiation sensitivity in caspase DKO cells may be due
to alternative programmed cell death such as autophagy [8]. To
test this hypothesis, WT and caspase 3/7 DKO cells were
transfected with GFP-LC3 plasmid. Cells with punctate GFP
signaling were counted as autophagic cells because of the
characteristic lysosomal localization of LC3 protein during
autophagy [19]. After WT and caspase DKO cells were exposed
to 5Gy of radiation, the percentage of cells with GFP punctates
were increased approximately 3-fold in irradiated caspase DKO
cells, as compared to irradiated WT cells (30% vs 10%,
respectively) (Figure 6A). At 48h post-radiation, the percentage
of autophagic cells increased to ,55% in caspase DKO cells
compared to 15% in WT control. These results were also
confirmed by assessing the level of processed LC3 protein, in
which the caspase DKO cells showed increased levels of LC3-I
and-II proteins following irradiation, in comparison to WT cells
(Figure 6B). Because the mTOR pathway is known to regulate
initiation of autophagy, we examined Akt/mTOR signaling by
determining the levels of phospho-Akt and phospho-S6 in the
irradiated WT and caspase DKO MEF cells. As shown in
Figure 6C, the phospho-proteins were increased in the irradiated
WT cells, whereas they were decreased in the irradiated caspase
DKO MEF cells. These data suggest that pro-autophagic signaling
is up-regulated in the irradiated caspase DKO cells.
Autophagy alters radiation sensitivity in caspase 3/7
deficient cells
To determine whether autophagy is the mechanism responsible
for higher radiosensitivity observed in caspase DKO cells,
Figure 5. Caspase 3/7 deficiency resulted in radiation sensitivity in the absence of apoptosis in MEF cells. (A) WT and Caspase 3/7 DKO
MEFs were incubated with Annexin V-fluorescein isothiocyanate and propidium iodide 24 h after irradiation and analyzed by FACScan. Data are
shown as the mean of three experiments S.D. (B) Caspase cleavage was determined by immunoblotting of cleaved caspase-3 after WT or Caspase 3/7
DKO MEF cells were treated with 0, 2.5, 5, 7.5, and 10 Gy. The cells were harvested after 24. (C) Radiosensitization of WT or Caspase 3/7 DKO MEFs. The
cells were irradiated with the indicated doses of radiation and treated with DMSO control or M867 (dose range from 5 to 10 nM, for 24hrs). After
10 days, colonies were stained and scored. Reported values are mean6S.D. of three separate repeated experiments.
doi:10.1371/journal.pone.0002275.g005
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PLoS ONE | www.plosone.org 8 May 2008 | Volume 3 | Issue 5 | e2275Figure 6. Autophagy in irradiated Caspase 3/7 DKO MEFs and effects on radiosensitivity. (A) GFP-LC3-transfected WT or Caspase 3/7 DKO
MEF cells were treated with and without 5 Gy and then examined by fluorescence microscopy after 24 h. The percentage of cells with punctate GFP-
LC3 fluorescence was calculated relative to all GFP-positive cells. Error bars are shown as mean S.D. (B) LC-I and –II expression was determined by
Western blot using lysates from WT and Caspase 3/7 DKO MEF cells treated with 0 or 5 Gy after 24, 48 h. Actin was probed to demonstrate equal
loading. (C) Also shown are immunoblots of phospho-Akt and p-S6 using the lysates from WT and Caspase 3/7 DKO MEF cells treated with 0 or 5 Gy
after 30 min. (D) WT and Caspase 3/7 DKO MEF cells were transfected with either control siRNA or 25 nM siRNAs directed against ATG5 and Beclin-1
or (E) transfected with vector or ATG5 and Beclin-1 cDNA containing plasmids. They were then irradiated with 0 to 6 Gy. After 8 days, colonies were
stained and scored. Values shown are the mean6S.D. of three separate repeated experiments.
doi:10.1371/journal.pone.0002275.g006
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proteins [21,22,23], were knocked down in wild type and caspase
DKO cells. Previous studies showed that siRNA against Beclin-1
and ATG-5 specifically downregulated endogenous protein
expression [8]. As shown in Figure 6D, treatment of caspase
DKO cells with siRNAs directed against ATG-5 and Beclin-1
abolished the sensitizing effect resulting from caspase-3/7 deletion
and caused significant increase in clonogenic cell survival as
compared to control siRNA treatment of caspase DKO cells
(DER=1.34, p=0.008). Conversely, overexpression of Beclin-1
and ATG-5 in caspase DKO cells caused significant increase in
clonogenic cell death under increasing radiation dose as compared
to Beclin-1 and ATG-5 overexpression in WT cells (DER=1.32,
p=0.008) (Figure 6E). Together, these results demonstrate that
increased radiosensitivity in caspase DKO cells is dependent on
key autophagy molecules.
Discussion
In the present report, we first showed that M867 treatment
resulted in the effective radiosensitization of lung cancer cells in
vitro. The potential therapeutic effects by M867 were then
demonstrated in an in vivo mouse hind limb tumor model. Further
in vitro experiments showed that caspase-3/7-null MEF cells, were
more sensitive to the cytotoxic effects of radiation, primarily due to
increased autophagy. This study also suggests that M867 effects on
vasculature may contribute to the observed increase in lung tumor
growth delay in response to radiation.
Concurrent chemoradiotherapy is a mainstay in the treatment
of advanced lung cancer, but the prognosis for those patients
remains globally poor. Therefore, novel strategies are needed to
improve the current treatment effectiveness by targeting of non-
apoptotic cell death since apoptosis is limited following conven-
tional therapy. Recently, there has been a great emphasis placed
on autophagy as a cancer therapy target, partly driven by
observations that anticancer treatments induced autophagy, such
as in irradiated cancer cells [17,24]. We showed recently that
autophagy can be triggered by inhibiting the mammalian target or
rapamycin (mTOR) pathway [17] or by inhibiting pro-apoptotic
proteins Bak/Bax to enhance radiation effects in vitro [8]. A very
attractive target in the apoptotic pathway is caspase-3, which has a
central role in apoptosis as the dominant effector caspase involved
in the proteolytic cleavage of protein substrates including
cytoskeletal proteins, kinases and DNA repair enzymes. In this
study, we analyzed the potential effects of caspase-3 inhibition on
lung cancer response to radiation using the novel inhibitor M867.
We showed that the administration of M867 in combination with
ionizing radiation decreased dramatically the survival of H460
lung cancer cells (Figure 1), in a dose-dependent manner. Of note,
we observed increased cytotoxicity at concentration higher than
10nM in our clonogenic assay. Nevertheless, it has been shown
that M867 is a potent and reversible caspase-3 inhibitor (IC50 of
0.0001 mM), and a less potent caspase-7 inhibitor (IC50 of
0.036 mM) [18]. In addition, we found that the radiosensitizing
effect of M867 is dependent upon caspase-3 and -7, as
demonstrated by the absence of its impact upon caspase 3/7
DKO cells. Our study showed that increased levels of apoptosis
were observed following increased doses of radiation alone in cell
culture, a dose as high as 20Gy only yielded 20% of apoptotic
H460 cells (Figure 1B). M867 was able to inhibit apoptosis to half
at a comparable concentration (100nM) as used by Methot et al
[20]. It was administered for two hours to minimize cytotoxicity.
This observation is consistent with previous studies reporting the
existence of defective apoptotic pathway in lung cancer. Deficient
apoptosis has been long viewed as a mechanism for therapeutic
resistance. Surprisingly, M867 not only reduced apoptosis
following irradiation, but also to reduced tumor cell proliferation,
as depicted by the Ki67 immunostaining (Figure 3A). These results
can be viewed as a paradox, especially if apoptosis is the only
measure of therapeutic efficacy. As we know, recent published
data showed that apoptosis may account for less than 20% of
radiation-induced cell death [7].
In addition, alternative death pathway such as autophagy has
been demonstrated in irradiated cancer cells [17,24]. Consistent
with these results, potentiation of radiation sensitivity by vitamin
D3 analogue EB 1089 has been reported in breast tumor cells via
autophagy cell death [25]. In light of these data, caspase-
independent cell death such as autophagy can explain the
promotion of cytotoxicity in our xenograft model.
The mechanism of M867 on the radio-response in lung cancer
was further characterized using a caspase-3/7 DKO model. Our
results suggest the role of autophagy in the modulation of cellular
sensitivity to ionizing radiation, and increased level of autophagy
was determined as the possible cause of radiosensitivity when
caspase 3/7 are deficient. As shown, irradiated DKO cells had
elevated autophagic activity. The down-regulation or up-regula-
tion of pro-autophagic proteins ATG5 and Beclin-1 resulted in a
reduced or greater radiosensitization, respectively (Figure 6).
Additionally, our results support the potential effects of M867
on the tumor microenvironment. As shown in Figure 3A, M867
treatment alone was able to decrease Ki67 index, possibly by an
effect on angiogenesis. Indeed, neovascularisation is a crucial step
for tumor development, and progression of lung cancer, and high
microvessel density has been identified as a prognostic factor
predictive of metastasis and poor survival [26]. As shown by vFW
staining (Figure 4A), the combination M867/radiation further
reduced the vessels density compared to radiation alone. Our
results are consistent with a report showing that blockage of
caspase activity produces alterations in the normal angiogenic
pattern, which suggest that active caspase may participate in
angiogenesis by allowing the formation of a new functional blood
vessel network [27]. As we know, cell motility and migration are
critical steps of angiogenesis [28]. Interestingly, two very recent
reports may bring some lights on the possible link between
inhibition of caspase activity and the significant anti-angiogenic
effects observed with M867. The first report showed that caspase-8
can regulate cell adhesion and motility [29]. The other study
demonstrated that glioblastoma cells exhibit a basal constitutive
caspase activity that is sufficient to promote migratory and invasive
activities [30]. These results suggest that activation of caspases
following pro-apoptotic therapy may enhance metastasis or
invasiveness of apoptosis-resistant cancer cells. This would lead
us to speculate that instead of inducing cancer cytotoxicity, such
treatment may unexpectedly promote tumor migration and
metastasis. Therefore, M867 may serve to suppress these
unwanted consequences in irradiated cancer cells which survived
apoptotic cell death. We also examined the effect of M867 on the
angiogenic function of HUVECs in vitro, using an endothelial cell
morphogenesis assay (Figure 4, B and C). The bi-modality
treatment decreased the ability of endothelial cells to form
capillary tubule-like structures compared with M867 or radiation
alone. One of the molecular mechanisms for radioresistance is the
production of pro-angiogenic factors such as the vascular
endothelial growth factor (VEGF), fibroblast growth factor (FGF)
and platelet-derived growth factor (PDGF) following irradiation
[31,32,33,34]. Radiation-induced activation of angiogenesis thus
attenuates vasculature damage under radiotherapy and potentially
limits the effectiveness of this anticancer modality. As a
Caspase Inhibition
PLoS ONE | www.plosone.org 10 May 2008 | Volume 3 | Issue 5 | e2275fundamental step in tumorigenesis and in radioresistance,
angiogenesis represents an attractive therapeutic target, and this
report shows that M867 provides an effective means of inhibiting
neovascularisation in irradiated lung tumor models.
The stimulation of autophagy was shown to enhance radiation
cytotoxicity in cancer cells [35,36]. A similar effect on vasculature
was supported by a report from Chau et al that showed autophagic
cell death also inhibits angiogenesis [37]. PTEN, a tumor
suppressor protein frequently inactivated in cancer, is associated
with autophagy, and was found to suppress tumor neovascular-
ization in an in vivo brain tumor model [38]. Loss of PTEN leads
to the enhancement of tumor angiogenesis in mouse endothelial
cells [36]. These data support our conclusion that cancer therapy
can be enhanced by promotion of autophagy within both cancer
cells and the vasculature.
A major limitation in delivering thoracic radiotherapy for lung
cancer is to achieve an optimal radiation dose for maximum
tumoricidal effect without injuring the normal lung tissue.
Radiation pneumonitis, an interstitial pulmonary inflammation
that develops in up to 30% of patients after thoracic irradiation
[39], and subsequent interstitial lung fibrosis [40] are challenging
dose-limiting toxicities of radiation therapy for lung cancer. Thus,
the development of a strategy that could protect lung from
radiation pneumonitis and fibrosis would offer the possibility of
improving the therapeutic ratio of patients with lung cancer.
Several caspases have been associated with inflammatory diseases
and mediation of pro-inflammatory cytokines [41]. Moreover,
there is increasing evidence that apoptosis might play a role in
several pulmonary diseases [42], including fibrosing pulmonary
diseases, and bronchiolitis obliterans-organizing pneumonia [40].
Fas/FasL-mediated lung epithelial apoptosis can lead to inflam-
mation and progression from ARDS to fibrosis [42]. A role of
TGF-beta 1 in the pathophysiology of pulmonary fibrosis as an
enhancer of Fas-mediated apoptosis of lung epithelial cells and
lung injury via caspase-3 activation was also previously demon-
strated in mice [43]. It is also well known that irradiation of the
lungs results in an increased expression of TGF-beta which has
been reported to be related to the development of radiation-
induced pneumonitis and fibrosis [44]. One could thus hypoth-
esize that the inhibition of caspase may protect healthy
surrounding lung tissues against thoracic radiation injury. This
hypothesis is also based on the high apoptosis level found in
irradiated normal lung cells as compared to the lung cancer cells
which are resistant to apoptosis. This possible radio-protective role
of caspase inhibition deserve further pre-clinical study using, for
example, C57BL/6 mice [45,46]. More precisely, C57BL/6 mice
that express wild-type levels of ICAM-1 show pulmonary
inflammation following thoracic irradiation beginning within
4 weeks of irradiation, whereas C57BL/6 mice that lack ICAM-
1 gene expression do not develop inflammation.
This preclinical study not only supports the significant
therapeutic potential of M867 as a radiosensitizer in lung cancer
but also suggest caspase inhibition as a novel concept for the
enhancement of radiation therapy in cancer. This promising
strategy needs further specific radiotherapy-driven experiments
and clinically relevant study to explore novel combinations using
this proof-of-principle.
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